Luyan Pharma - Public Comps and Valuation Multiples

Luyan Pharma Overview

About Luyan Pharma

Luyan Pharma Co Ltd engages in the production, operation, distribution, and retail of human health products in China. It provides medical and health products.

Founded

2008

HQ

Employees

5.6K+

Website

luyan.com.cn

Sectors

Pharmacies

Financials

Last FY Revenue $2.9B

Last FY EBITDA $111M

EV

$1.1B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Luyan Pharma Financials

See Luyan Pharma valuation multiples based on analyst estimates

Luyan Pharma P&L

In the most recent fiscal year, Luyan Pharma reported revenue of $2.9B and EBITDA of $111M.

Luyan Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Luyan Pharma valuation multiples based on analyst estimates

	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	XXX	$2.9B	XXX	XXX	XXX
Gross Profit	XXX	$214M	XXX	XXX	XXX
Gross Margin	XXX	7%	XXX	XXX	XXX
EBITDA	XXX	$111M	XXX	XXX	XXX
EBITDA Margin	XXX	4%	XXX	XXX	XXX
EBIT	XXX	$96.9M	XXX	XXX	XXX
EBIT Margin	XXX	3%	XXX	XXX	XXX
Net Profit	XXX	$48.5M	XXX	XXX	XXX
Net Margin	XXX	2%	XXX	XXX	XXX
Net Debt	XXX	$553M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Luyan Pharma including revenue, profitability, and margin analysis across different time periods. In the most recent fiscal year, Luyan Pharma achieved $2.9B in revenue and $111M in EBITDA.
Financial Metric	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	Analyst estimates available to subscribers	$2.9B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	Analyst estimates available to subscribers	$214M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	Analyst estimates available to subscribers	7.4% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	Analyst estimates available to subscribers	$111M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	Analyst estimates available to subscribers	3.9% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	Analyst estimates available to subscribers	$96.9M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	Analyst estimates available to subscribers	3.4% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	Analyst estimates available to subscribers	$48.5M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	Analyst estimates available to subscribers	1.7% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	$553M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Luyan Pharma

This financial data table provides comprehensive performance metrics for Luyan Pharma, a company based in China. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Fiscal Year Performance

In the most recent fiscal year, Luyan Pharma reported $2.9B in total revenue.
Fiscal year EBITDA was $111M.
The company maintained a gross profit margin of 7.4% in the most recent fiscal year.
EBITDA margin for the fiscal year was 3.9%.
Net profit margin reached 1.7% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Luyan Pharma. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Luyan Pharma Stock Performance

Luyan Pharma has current market cap of CNY 3.3B (or $464M), and EV of CNY 7.8B (or $1.1B).

Market Cap Evolution

Luyan Pharma Stock Data

As of September 15, 2025, Luyan Pharma's stock price is CNY 9 (or $1).

See Luyan Pharma trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$1.1B	$464M	XXX	XXX	XXX	XXX	n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Luyan Pharma Valuation Multiples

Luyan Pharma's trades at 0.4x EV/Revenue multiple, and 9.8x EV/EBITDA.

See valuation multiples for Luyan Pharma and 15K+ public comps

Luyan Pharma Financial Valuation Multiples

As of September 15, 2025, Luyan Pharma has market cap of $464M and EV of $1.1B.

Equity research analysts estimate Luyan Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Luyan Pharma's P/E ratio is not available.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$464M	XXX	$464M	XXX	XXX	XXX
EV (current)	$1.1B	XXX	$1.1B	XXX	XXX	XXX
EV/Revenue	n/a	XXX	0.4x	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	9.8x	XXX	XXX	XXX
EV/EBIT	n/a	XXX	11.2x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	n/a	XXX	9.6x	XXX	XXX	XXX
EV/FCF	n/a	XXX	35.9x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Luyan Pharma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Luyan Pharma Margins & Growth Rates

Luyan Pharma's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $21K for the same period.

Luyan Pharma's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Luyan Pharma's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Luyan Pharma and other 15K+ public comps

Luyan Pharma Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	4%	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	n/a	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.5M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$21K	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	0%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	0%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	4%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial